Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STM-416p
- Development stage
- Phase 1
- Lead developer
- SURGE Therapeutics
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Intraoperative, Intralesional
01
Overview
STM-416p is an intraoperative immunotherapy being developed by SURGE Therapeutics for prostate cancer patients undergoing radical prostatectomy. It utilizes SURGE's injectable biodegradable hydrogel technology to enable extended, localized release of resiquimod (an imidazoquinolinamine that targets TLR7 and TLR8) directly at the site of surgical tumor resection. This approach aims to reprogram the body's response to surgery from immunosuppressive to immunostimulatory, triggering the patient's immune system to destroy residual cancer cells and prevent recurrence.
02
Targets
TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on STM-416p.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STM-416p.